Premature Ejaculation - Pipeline Review, H2 2016

Date: October 29, 2016
Pages: 53
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P133AABB0D4EN
Leaflet:

Download PDF Leaflet

Premature Ejaculation - Pipeline Review, H2 2016
Premature Ejaculation - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation - Pipeline Review, H2 2016, provides an overview of the Premature Ejaculation (Male Health) pipeline landscape.

Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Ejaculation - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively for Premature Ejaculation.

Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Ejaculation (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Premature Ejaculation (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Premature Ejaculation (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Premature Ejaculation (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Premature Ejaculation (Male Health)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Premature Ejaculation Overview
Therapeutics Development
Pipeline Products for Premature Ejaculation - Overview
Premature Ejaculation - Therapeutics under Development by Companies
Premature Ejaculation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Premature Ejaculation - Products under Development by Companies
Premature Ejaculation - Companies Involved in Therapeutics Development
Allergan Plc
Ixchelsis Limited
NeuroHealing Pharmaceuticals Inc.
Plethora Solutions Holdings Plc
SK Chemicals Co., Ltd.
Premature Ejaculation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(lidocaine + prilocaine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Ejaculation - Dormant Projects
Premature Ejaculation - Discontinued Products
Premature Ejaculation - Product Development Milestones
Featured News & Press Releases
Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation
Nov 11, 2014: Plethora Solutions Provides Company Update
Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
Mar 11, 2014: Plethora Solutions Provides Company update
Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update
Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502
Dec 19, 2011: Plethora Provides Update On PSD502
Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation
May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting
Nov 19, 2009: Sciele Pharma Presents Pivotal Study For PSD502, The First Potential Treatment For Premature Ejaculation At The Sexual Medicine Society Of North America (SMSNA)
Aug 21, 2009: NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 53

LIST OF TABLES

Number of Products under Development for Premature Ejaculation, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Premature Ejaculation - Pipeline by Allergan Plc, H2 2016
Premature Ejaculation - Pipeline by Ixchelsis Limited, H2 2016
Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2016
Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H2 2016
Premature Ejaculation - Pipeline by SK Chemicals Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Premature Ejaculation - Dormant Projects, H2 2016
Premature Ejaculation - Discontinued Products, H2 2016 41

LIST OF FIGURES

Number of Products under Development for Premature Ejaculation, H2 2016
Number of Products under Development by Companies, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Premature Ejaculation - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Retinopathy Of Prematurity - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 53 pages
Pancreatitis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 76 pages
Ziarco Pharma Ltd - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 27 pages

Ask Your Question

Premature Ejaculation - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: